Johnson & Johnson (JNJ)
(Real Time Quote from BATS)
$152.28 USD
-2.36 (-1.53%)
Updated May 20, 2024 12:12 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Johnson & Johnson - Hold
Zacks' proprietary data indicates that Johnson & Johnson is currently rated as a Zacks Rank 3 and we are expecting an inline return from the JNJ shares relative to the market in the next few months. In addition, Johnson & Johnson has a VGM Score of C (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Valuation metrics show that Johnson & Johnson may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.
Style Scorecard
Value Scorecard
Growth Scorecard
Momentum Scorecard
Value Score | JNJ: B | Industry [X] | RHHBY: C | MRK: C | PFE: B |
---|---|---|---|---|---|
Zacks Rank | 3 | 4 | 3 | 3 | |
VGM Score | C | C | A | C | |
Cash/Price | 0.07 | 0.05 | NA | 0.02 | 0.07 |
EV/EBITDA | 15.91 | 19.47 | NA | 62.11 | 28.81 |
PEG Ratio | 2.55 | 1.66 | 5.42 | 1.68 | 1.22 |
Price/Book (P/B) | 5.32 | 5.84 | 6.64 | 8.22 | 1.75 |
Price/Cash Flow (P/CF) | 11.32 | 10.54 | 10.56 | 43.12 | 9.62 |
P/E (F1) | 14.53 | 14.53 | 13.28 | 15.13 | 12.15 |
Price/Sales (P/S) | 4.15 | 4.66 | NA | 5.41 | 2.95 |
Earnings Yield | 6.88% | 6.88% | 7.53% | 6.61% | 8.24% |
Debt/Equity | 0.36 | 0.69 | 0.75 | 0.77 | 0.66 |
Cash Flow ($/share) | 13.66 | 4.62 | 3.11 | 3.04 | 2.98 |
Growth Score | JNJ: C | Industry [X] | RHHBY: C | MRK: B | PFE: F |
---|---|---|---|---|---|
Zacks Rank | 3 | 4 | 3 | 3 | |
VGM Score | C | C | A | C | |
Hist. EPS Growth | 5.81% | 5.81% | NA% | -12.34% | 3.17% |
Proj. EPS Growth | 7.29% | 7.29% | -4.26% | 474.12% | 28.15% |
Curr. Cash Flow Growth | -3.27% | 1.35% | -3.49% | -66.36% | -60.72% |
Hist. Cash Flow Growth | 2.38% | 3.34% | 0.87% | -13.74% | -6.96% |
Current Ratio | 1.17 | 1.21 | 1.35 | 1.25 | 1.05 |
Debt/Capital | 26.37% | 40.97% | 42.72% | 43.51% | 39.85% |
Net Margin | 45.26% | 13.30% | NA% | 3.76% | -0.56% |
Return on Equity | 36.70% | 30.42% | NA% | 14.05% | 8.64% |
Sales/Assets | 0.51 | 0.48 | NA | 0.58 | 0.25 |
Proj. Sales Growth (F1/F0) | -5.10% | 3.99% | 4.34% | 7.23% | 3.64% |
Momentum Score | JNJ: F | Industry [X] | RHHBY: F | MRK: A | PFE: B |
---|---|---|---|---|---|
Zacks Rank | 3 | 4 | 3 | 3 | |
VGM Score | C | C | A | C | |
Daily Price Chg | 0.23% | -0.06% | 0.49% | 0.24% | -0.97% |
1 Week Price Chg | 3.16% | 1.78% | 6.01% | 0.87% | 2.25% |
4 Week Price Chg | 4.55% | 7.19% | 7.89% | 4.30% | 10.15% |
12 Week Price Chg | -4.45% | 0.48% | -0.46% | 1.34% | 3.17% |
52 Week Price Chg | -2.69% | 2.28% | -18.02% | 13.59% | -22.11% |
20 Day Average Volume | 7,723,419 | 3,584,434 | 3,040,324 | 7,281,761 | 44,605,976 |
(F1) EPS Est. Wkly Chg | 0.00% | 0.00% | 0.00% | -0.08% | 0.00% |
(F1) EPS Est. Mthly Chg | -0.06% | 1.35% | -0.10% | 1.35% | 6.94% |
(F1) EPS Est. Qtrly Chg | -0.10% | 1.06% | -6.88% | 1.06% | 7.56% |
(Q1) EPS Est. Mthly Chg | -0.03% | -0.03% | NA% | 2.26% | -3.42% |
Zacks News for JNJ
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services